FDA

FDA warns 30 telehealth firms over misleading marketing of compounded GLP-1s

March 4, 2026

FDA issued 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP‑1 products sold online. Violations included implying these compounds are the same as FDA‑approved drugs and obscuring product sourcing by branding products with the telehealth firm’s own name. FDA Commissioner Marty Makary, M.D., M.P.H., said compounding can help address shortages or unique patient needs but should not be used to bypass the FDA approval process. This marks the second wave of enforcement since the agency launched its September crackdown on misleading direct‑to‑consumer pharmaceutical ads, during which it has issued thousands of warning letters—more than in the previous decade combined. The agency reiterated that compounded drugs are not FDA‑approved and differ from generic medications that undergo FDA review for safety, effectiveness, and quality.

Source:

(2026, March 3). FDA. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s [Press Announcement]. https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s